secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2024-10-03T23:59:59+00:00
Accession:  0001140361-24-042652
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q1 FY2025 net sales $67.5M (+1.1% pro forma); GAAP EPS -$0.31, adj. EPS -$0.11
--------------------------------------------------------------------------------

- Med Tech segment sales $28.0M (+8.7% YoY) driven by Auryon at $13.7M (+24.9%) and AlphaVac at $2.2M (+21.1%).
- Med Device segment sales $39.5M (-3.6% YoY); U.S. Med Device grew 2.1%.
- GAAP net loss $12.8M ($0.31 loss/share); adjusted net loss $4.4M ($0.11 loss/share).
- Submitted NanoKnife PRESERVE study to FDA for 510(k) prostate tissue indication; received CE Mark for Auryon in Europe.
- FY2025 guidance reaffirmed: net sales $282-288M, adj. EBITDA loss $2.5M-$0, adj. EPS loss $0.38-$0.42.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124042652/0001140361-24-042652-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124042652/ef20036580_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-042652

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer